StreetInsider.com News Articles

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time.

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical to Present at Upcoming Investor Summit Conference

Mon, 22 Jun 2026 08:45:00 -0400

Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations

A replay of the SeaStar Medical presentation will be available on the Company's

SeaStar Medical Holding Corp. (ICU) PT Raised to $8 at Maxim Group

Thu, 14 May 2026 08:53:56 -0400

Maxim Group analyst Anthony Vendetti raised the price target on SeaStar Medical Holding Corp. (NASDAQ: ICU) to $8.00 (from $6.00) while maintaining a Buy rating.

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

DENVER, May 13, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Wed, 13 May 2026 16:05:00 -0400

Added 7 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue

Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI

Initiated efforts for the submission of a modular post-marketing application (PMA)

Webcast today at 4:30 pm Eastern Time